He Won the Nobel Prize for Protein Design. Now He Uses AI to Create Molecules Not Found in Nature

AI can now design biological molecules and functions that do not exist in nature, offering potential cures and environmental solutions.

David Baker, a Nobel laureate in Chemistry for protein design, is now leading an initiative to use AI to create novel molecules and biological functions previously undiscovered in nature. This project, spearheaded by the Allen Institute in collaboration with the University of Washington and the Fred Hutchinson Cancer Center, aims to develop future medicines, such as treatments for cancer and neurodegenerative diseases, and technologies like plastic-degrading enzymes. Baker's team at AI BioDesign leverages computational design to predict and evaluate risks associated with these novel biological entities before they are synthesized. The approach represents a significant departure from traditional biology, which has primarily focused on studying evolution's existing solutions, and is being compared to transformative historical technological advancements. The researchers are developing databases, models, and tools to enable these future innovations, with a focus on addressing challenges in health, sustainability, and human well-being, while also establishing governance structures to mitigate potential misuse and unintended consequences.

This endeavor marks a profound shift from studying nature's evolved solutions to actively designing entirely new biological components. It signifies a move into uncharted biological territory, with potential applications ranging from rapid disease cures to environmental remediation. The comparison to industrialization and electrification underscores the magnitude of transformation this field anticipates. However, the exploration of novel biological regions also necessitates robust risk assessment and governance frameworks to manage unintended consequences, misuse, and environmental impact, even when the underlying mechanisms are not fully understood.

The ability to computationally design and evaluate molecules before synthesis offers a critical advantage in mitigating risks associated with novel biotechnologies. This predictive power is essential for developing applications that address global challenges like disease and pollution. Future innovations could enable cures for new diseases in weeks, improve environmental quality through pollutant breakdown, enhance crop resilience, and facilitate resource recovery from waste. The development of such advanced tools, coupled with potential governance strategies like synthetic DNA logging, aims to balance the pursuit of groundbreaking biological engineering with the imperative of safety and ethical responsibility.